Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13052990 | 0.77 | TSHR (0.39) | TSHRSLC1A1L3MBTL1CA12CA14 | |
| SCHEMBL14733286 | 0.76 | L3MBTL1 (0.42) | TSHRL3MBTL1KMT2ALMNAALDH1A1 | |
| SCHEMBL15073419 | 0.72 | TSHR (0.50) | TSHRSLC1A1L3MBTL1CA12CA14 | |
| SCHEMBL27562398 | 0.72 | TSHR (0.55) | TSHRSLC1A1L3MBTL1CA12CA14 | |
| SCHEMBL3685300 | 0.70 | TSHR (0.52) | TSHRSLC1A1L3MBTL1CA12CA14 | |
| SCHEMBL12951352 | 0.70 | TSHR (0.52) | TSHRSLC1A1L3MBTL1CA12CA14 | |
| SCHEMBL14733285 | 0.70 | LMNA (0.47) | TSHRL3MBTL1CA12CA14CA7 | |
| SCHEMBL20804234 | 0.69 | ALDH1A1 (0.36) | TSHRL3MBTL1KMT2AMEN1LMNA | |
| SCHEMBL14734042 | 0.69 | L3MBTL1 (0.47) | TSHRL3MBTL1KMT2ALMNAALDH1A1 | |
| SCHEMBL28360019 | 0.69 | TSHR (0.50) | TSHRSLC1A1L3MBTL1CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835663-B2 | Lubricity improver | KOREA INSTITUTE OF PETROLEUM MANAGEMENT (KR) | 2014-09-16 | — | — | US | disclosed |
| US-20130053590-A1 | LUBRICITY IMPROVER | KOREA INSTITUTE OF PETROLEUM MANAGEMENT (KR) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053590-A1 | LUBRICITY IMPROVER | ELOVL1, ELOVL5, FASN | TSHR 4404/4885SLC1A1 4248/4885L3MBTL1 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.